HuLA immune(フライミューン)株式会社についてのページです。患者さんに笑顔になっていただくことを使命にした大阪大学発のバイオベンチャーです

HuLA immune(フライミューン株式会社)へはお気軽にお問い合わせ下さい

About us

History of the Company

March 2017 Incorporated as a result of governmental startup assistance program ( JST-START )
March 2017 Entered into the joint study agreement for innovative medicines based on the theory which is originated from Dr.Arase with Osaka University Arase Laboratory
December 2018 Capital injected by the Osaka Univ. Venture Capital Co., Ltd. and Mitsubishi UFJ Capital Co., Ltd.
November 2019 Entered into the joint research agreements with Meiji Seika Pharma Co.,Ltd. for 2 specific diseases. (see TOPICS)

Board Members and Adviser

Yasuhiro Shindo, Ph.D. President and CEO
Yoshiyuki Osugi, Ph.D. Director
Akihiro Tomoyasu, Ph.D. Director
Fumio Nishikaku, Ph.D. Director
Shigeru Yasue Director
Kazuhiro Akiyama Auditor
Hisashi Arase, M.D., Ph.D. Technical Adviser

Structure of the Company

Shareholders’ Meeting General - Board Meeting - Auditor - Technical Adviser - C E O - Drug Discovery Research Center - Business Promotion Dept - Administrative Dept


Head Office
SENQ Kasumigaseki,1-4-1 Kasumigaseki,Chiyoda-ku, Tokyo
Drug Discovery Research Center
c/o Research Institute for Microbial Diseases of Osaka Univ.
3-1 Yamadaoka,Suita,Osaka 565-0871,Japan